Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization

Journal of the American College of Cardiology

Volumn 30, Issue 1, 1997, Pages 149-156

  Lincoff, A Michael ^a   Califf, Robert M ^b   Anderson, Keaven M ^c   Weisman, Harlan F ^c   Aguirre, Frank V ^d   Kleiman, Neal S ^e   Harrington, Robert A ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CENTOCOR INC   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; HEPARIN; NITRATE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHERECTOMY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK; TREATMENT OUTCOME;

EID: 0030738122     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00110-1     Document Type: Article

References (34)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med. 326:1992;242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med. 326:1992;310-318.
3. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty natural history of the pathophysiological response to injury in a pig model . Circ Res. 57:1985;105-112.
4. Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J. 117:1989;769-776.
5. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey S, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris a report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry . J Am Coll Cardiol. 24:1994;1195-1206.
6. de Feyter PJ, Serruys PW, van den Brand M, Hugenholtz PG. Percutaneous transluminal coronary angioplasty for unstable angina. Am J Cardiol. 68:1991;125-135B.
7. Grassman ED, Leya F, Johnson SA, et al. Percutaneous transluminal coronary angioplasty for unstable angina predictors of outcome in a multicenter study . J Thromb Thrombolysis. 1:1994;73-78.
8. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina angiographic assessment and thrombolytic therapy during ongoing anginal attacks . Circulation. 77:1988;526-534.
9. Lewis HDJ, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina results of the Veterans Administration Cooperative Study . N Engl J Med. 309:1983;396-403.
10. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 313:1985;1369-1375.
11. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
12. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
13. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 318:1988;1714-1719.
14. Collaborative overview of randomised trials of antiplatelet therapy. I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients . BMJ. 308:1994;81-106.
15. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 71:1988;831-843.
16. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 76:1985;101-108.
17. 2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 66:1985;1456-1459.
18. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
19. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
20. Topol EJ, Califf RM, Weisman HS, et al. Reduction of clinical restenosis following coronary intervention with early administration of platelet IIb/IIIa integrin blocking antibody. Lancet. 343:1994;881-886.
21. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial - phase I hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase . J Am Coll Cardiol. 11:1988;1-11.
22. Landefeld LS, Cook EF, Hatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 82:1987;703-713.
23. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation. 94:1996;629-635.
24. Neter J, Wasserman W. Applied Linear Statistical Models. 1974;Richard D. Irwin, Inc, Homewood (IL).
25. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 75:1995;559-562.
26. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 91:1995;2882-2890.
27. The TIMI III, Investigators B. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction results of the TIMI IIIB trial . Circulation. 89:1994;1545-1556.
28. Wallentin L, Ohlsson J, Swahn E. Low molecular weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
29. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Circulation. 90:1994;613-622.
30. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 24:1994;39-45.
31. Serruys PW, Herrman J-PR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 333:1995;757-763.
32. Bittl JA, Strony J, Brinker JA, et al. Treatment with Bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 333:1995;764-769.
33. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina results of the TAUSA trial . Circulation. 90:1994;69-77.
34. Lincoff AM, Tcheng JE, Califf RM, et al. Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention final results of the EPILOG trial [abstract] . J Am Coll Cardiol. 29:(Suppl A):1997;187A.